Prescribed drugs sit able to be distributed to sufferers at 986 Pharmacy, an unbiased pharmacy in Alhambra, Calif.

Jackie Fortiér/KFF Well being Information

disguise caption

toggle caption

Jackie Fortiér/KFF Well being Information

Within the dim basement of a Salt Lake Metropolis pharmacy, a whole bunch of amber-colored plastic tablet bottles sit stacked in rows, one man’s defensive wall in a tariff battle.

Unbiased pharmacist Benjamin Jolley and his colleagues fear that tariffs geared toward bringing drug manufacturing to the USA may as a substitute drive corporations out of enterprise whereas elevating costs and creating extra of the drug shortages which have plagued American sufferers for a number of years.

Jolley purchased six months’ value of the most costly massive bottles, hoping to defend his enterprise from the ten% across-the-board tariffs on imported items that President Trump introduced April 2. Now with threats of extra tariffs focusing on prescribed drugs, Jolley worries that prices will soar for the medicines that may fill these bottles.

In precept, Jolley mentioned, utilizing tariffs to push manufacturing from China and India to the U.S. is smart. Within the occasion of battle, China may shortly cease all exports to the USA.

“I perceive the rationale for tariffs. I am undecided that we’re gonna do it the suitable means,” Jolley mentioned. “And I’m undoubtedly positive that it’ll elevate the worth that I pay my suppliers.”

Squeezed by insurers and middlemen, unbiased pharmacists comparable to Jolley discover themselves on the entrance strains of a tariff storm. Practically everybody down the road — drugmakers, pharmacies, wholesalers and middlemen — opposes most tariffs.

Slashing drug imports may set off widespread shortages, consultants mentioned, due to America’s dependence on Chinese language- and Indian-made chemical components, which kind the essential constructing blocks of many medicines. Business officers warning that steep tariffs on uncooked supplies and completed prescribed drugs may make medication costlier.

“Massive ships do not change course in a single day,” mentioned Robin Feldman, a UC Legislation San Francisco professor who writes about prescription drug points. “Even when corporations pledge to carry manufacturing house, it should take time to get them up and working. The important thing might be to keep away from injury to business and ache to customers within the course of.”

On April 8, Trump mentioned he would quickly announce “a serious tariff on prescribed drugs,” which have been largely tariff-free within the U.S. for 30 years.

“Once they hear that, they’ll depart China,” he mentioned. The U.S. imported $213 billion value of medicines in 2024 — from China but in addition India, Europe and different areas.

Capsules sit within the tray of a pill-counting machine at 986 Pharmacy in Alhambra, Calif.

Jackie Fortiér/KFF Well being Information

disguise caption

toggle caption

Jackie Fortiér/KFF Well being Information

Trump’s assertion despatched drugmakers scrambling to determine whether or not he was critical, and whether or not some tariffs could be levied extra narrowly, since many elements of the U.S. drug provide chain are fragile, drug shortages are frequent, and upheaval on the FDA leaves questions on whether or not its staffing is satisfactory to examine factories, the place high quality issues can result in provide chain crises.

On Might 12, Trump signed an govt order asking drugmakers to carry down the costs People pay for prescriptions, to place them in step with costs in different international locations.

In the meantime, pharmacists predict even the ten% tariffs Trump has demanded will damage: Jolley mentioned a possible enhance of as much as 30 cents a vial just isn’t a king’s ransom, nevertheless it provides up once you’re a small pharmacy that fills 50,000 prescriptions a 12 months.

“The one phrase that I’d say proper now to explain tariffs is ‘uncertainty,'” mentioned Scott Tempo, a pharmacist and co-owner of Kavanaugh Pharmacy in Little Rock, Ark.

Arkansas pharmacist Scott Tempo visits Washington, D.C., to induce lawmakers and the Trump administration to lift reimbursements, warning that tariffs may in any other case hurt small, unbiased pharmacies like his.

Eric Harkleroad/KFF Well being Information

disguise caption

toggle caption

Eric Harkleroad/KFF Well being Information

To climate worth fluctuations, Tempo stocked up on the medication his pharmacy dispenses most.

“I’ve recognized the highest 200 generics in my retailer, and I’ve mainly put 90 days’ value of these on the shelf simply as a place to begin,” he mentioned. “These are the diabetes medication, the blood strain medicines, the antibiotics — these issues that I do know people might be sicker with out.”

Tempo mentioned tariffs could possibly be the loss of life knell for the numerous unbiased pharmacies that exist on “razor-thin margins” — except reimbursements rise to maintain up with greater prices.

Not like different retailers, pharmacies cannot move alongside such prices to sufferers. Their funds are set by well being insurers and pharmacy profit managers largely owned by insurance coverage conglomerates, who act as middlemen between drug producers and purchasers.

Neal Smoller, who employs 15 folks at his Village Apothecary in Woodstock, N.Y., just isn’t optimistic.

“It is not like they’re gonna return and say, effectively, this is your 10% bump due to the ten% tariff,” he mentioned. “Prices are gonna go up after which the sluggish responses from the PBMs — they will lead us to lose extra money at a quicker price than we already are.”

Smoller, who mentioned he has constructed a distinct segment promoting nutritional vitamins and dietary supplements, fears that FDA firings will imply fewer federal inspections and security checks.

“I fear that our pharmaceutical business turns into like our complement business, the place it is the Wild West,” he mentioned.

Narrowly targeted tariffs may work in some instances, mentioned Marta Wosińska, a senior fellow on the Brookings Establishment’s Middle on Well being Coverage. For instance, whereas drug manufacturing vegetation can price $1 billion and take three to 5 years to arrange, it might be comparatively low-cost to construct a syringe manufacturing unit — a enterprise American producers deserted through the COVID-19 pandemic as a result of China was dumping its merchandise right here, Wosińska mentioned.

It is not shocking that giants comparable to Novartis and Eli Lilly have promised Trump they’re going to make investments billions in U.S. vegetation, she mentioned, since a lot of their last drug product is made right here or in Europe, the place governments negotiate drug costs. The business is utilizing Trump’s tariff saber-rattling as leverage; in an April 11 letter, 32 drug corporations demanded European governments pay them extra or face an exodus to the USA.

Brandon Daniels, CEO of provide chain firm Exiger, is bullish on tariffs. He thinks they might assist carry some chemical manufacturing again to the U.S., which, when coupled with elevated use of automation, would cut back the labor benefits of China and India.

“You’ve got received actual property in North Texas that is cheaper than actual property in Shenzhen,” he mentioned at an financial convention April 25 in Washington, referring to a serious Chinese language chemical manufacturing middle.

However Wosińska mentioned no quantity of tariffs will compel makers of generic medication, chargeable for 90% of U.S. prescriptions, to construct new factories within the U.S. Cost buildings and competitors would make it financial suicide, she mentioned.

A number of U.S. generics corporations have declared chapter or closed U.S. factories over the previous decade, mentioned John Murphy, CEO of the Affiliation for Accessible Medicines, the generics commerce group. Reversing that development will not be straightforward and tariffs will not do it, he mentioned.

“There’s not a magic degree of tariffs that magically incentivizes them to return into the U.S.,” he mentioned. “There isn’t any room to make a billion-dollar funding in a home facility if you are going to lose cash on each dose you promote within the U.S. market.”

His group has tried to clarify these complexities to Trump officers, and hopes phrase is getting by way of. “We’re not PhRMA,” Murphy mentioned, referring to the highly effective commerce group primarily representing makers of brand-name medication. “I haven’t got the assets to go to Mar-a-Lago to speak to the president myself.”

Most of the energetic components in American medication are imported. Fresenius Kabi, a German firm with amenities in eight U.S. states to supply or distribute sterile injectables — important hospital medication for most cancers and different situations — complained in a letter to U.S. Commerce Consultant Jamieson Greer that tariffs on these uncooked supplies may paradoxically lead some corporations to maneuver completed product manufacturing abroad.

Fresenius Kabi additionally makes biosimilars, the generic types of costly biologic medication comparable to Humira and Stelara. The US is often the final developed nation the place biosimilars seem in the marketplace due to legal guidelines which might be extra beneficiant to the unique patent holders.

Tariffs on biosimilars coming from abroad — the place Fresenius makes such medication — would additional incentivize U.S. use of costlier brand-name biologics, the March 11 letter mentioned. Biosimilars, which might price a tenth of the unique drug’s worth, launch on common three to 4 years later within the U.S. than in Canada or Europe.

Along with getting cheaper knockoff medication quicker, European international locations additionally pay far lower than the USA for brand-name merchandise. Paradoxically, Murphy mentioned, those self same international locations pay extra for generics.

European governments have a tendency to determine extra steady contracts with makers of generics, whereas in the USA, “rabid competitors” drives down costs to the purpose at which a producer “perhaps scrimps on product high quality,” mentioned John Barkett, a White Home Home Coverage Council member within the Biden administration.

Consequently, Wosińska mentioned, “with out exemptions or different measures put in place, I actually fear about tariffs inflicting drug shortages.”

Smoller, the New York pharmacist, would not see any upside to tariffs.

“How do I clear up the issue of caring for my group,” he mentioned, “however not being topic to the emotional curler coaster that’s shelling out a whole bunch of prescriptions a day and watching each single considered one of them be a loss or 12 cents revenue?”

KFF Well being Information is a nationwide newsroom that produces in-depth journalism about well being points and is among the core working packages at KFF — the unbiased supply for well being coverage analysis, polling and journalism.